1Stamler J, O Vaccaro, JD Neaton, et al. Diabetes, other risk factors, and 12 - yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434- 444. 被引量：1
2Miller M, Seidler A, Kwiterovich PO, et al. Long term predicators of subsequent cardio vascular events with coronary artery disease and "Desirable" levels of plasma total cholerterol. Circulation 1992;86:1165. 被引量：1
3Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non- insulin dependent diabetes mellitus( UKPDS:23) :BMJ 1998;316:823-828. 被引量：1
4Howard BV, Robbins DC, Sievers ML, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong heart Study. Arterioscler Thromb Vasc Biol 2000;20:830- 835. 被引量：1
5Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lowvastatin in men and women with average cholesterol levels; results of AFCAPS/TexCAPS. JAMA 1998; 279:1615 - 1622. 被引量：1
6Pyorala K, Pederson TR, Kjekshus J et al. For the Scandinavian Simvastatin Survival Study: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study(4S).Diabetes Care 1997 ;20: 614 - 620. 被引量：1
7Goldberg RB, Mellies M J, Sacks FM, et al. For the CARE investigators: Cardiovascular events and their reduction with ravastatin in diabetic and glucose - intolerance myocardial infarction survivors with average cholesterol levels:subgroup analyses in the Cholesterol and Recurrent event(CARE)trial. Circulation 1998;98:2513-2519. 被引量：1
8The Long - Trem Intervention with Pravastatin in Ischaemic Disease(LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349 - 1357. 被引量：1
9Elkeles RS, diamond JR, Pouler C, et al. Cardiovascular outcomes in type 2 diabetes. A double - blind placebo - controlled study of bezafibrate: the St. Mary' s. Ealing, Northwick Park Diabetes cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21(4) :641 - 648. 被引量：1
10Bloomfield RH, Savenport J, Babikian V, et al. Reductuon in stroke with gemfibrozil in men with coronary heart disease and low HDL chloesterol: The Veterans affairs HDL Intervention Trial( VAHIT). Circulation 2001; 103(23) :2828 - 2833. 被引量：1
8[4]Haffner SM,D'Agostino R Jr.Mykkanen L,et al.Insulin sensitivity in subject with type 2 diabetes[J].Diabetes Care,1999,22(4):562 -568 被引量：1
9[5]Haring HU,Mehnert H.Pathogenesis of type 2 (non-insulin -dependent) diabetes mellitus:candidates for a signal transmitter defect causing insulin resistance of the skeletal muscle[J].Diabetologia,1993,36:176-182 被引量：1
10[8]Bonora E,Kiechl S,Willeit,et al.Prevalence of insulin resistance in metaolic disorders:the Burunech Study[J].Diabetes,1998,47(10):1643-1649 被引量：1
